KLP Kapitalforvaltning AS Has $1.89 Million Position in Hims & Hers Health, Inc. $HIMS

KLP Kapitalforvaltning AS raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 2.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 38,000 shares of the company’s stock after purchasing an additional 800 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Hims & Hers Health were worth $1,894,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. True Vision MN LLC grew its position in shares of Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock valued at $467,000 after purchasing an additional 328 shares during the period. Diligent Investors LLC grew its position in shares of Hims & Hers Health by 15.1% in the 2nd quarter. Diligent Investors LLC now owns 12,556 shares of the company’s stock valued at $626,000 after purchasing an additional 1,649 shares during the period. Matauro LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at approximately $446,000. Truist Financial Corp grew its position in shares of Hims & Hers Health by 20.7% in the 2nd quarter. Truist Financial Corp now owns 9,643 shares of the company’s stock valued at $481,000 after purchasing an additional 1,656 shares during the period. Finally, Janney Montgomery Scott LLC grew its position in shares of Hims & Hers Health by 15.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 10,019 shares of the company’s stock valued at $499,000 after purchasing an additional 1,311 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 7.3%

Shares of Hims & Hers Health stock opened at $53.98 on Monday. Hims & Hers Health, Inc. has a 12-month low of $17.36 and a 12-month high of $72.98. The stock has a market cap of $12.20 billion, a P/E ratio of 67.48, a P/E/G ratio of 3.65 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The business’s 50 day moving average is $50.86 and its 200-day moving average is $48.11.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HIMS shares. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Truist Financial cut their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and a consensus price target of $38.92.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 660,000 shares of the business’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company’s stock, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,608,588 shares of company stock valued at $83,020,063. 17.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.